NCT05765773进行中（未招募）2 期
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) for Adults Aged 60 Years and Older
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products13 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2021年7月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
- 试验地点
- 13
- 主要终点
- Frequency of development, type and association with vaccination of adverse events during the study.
研究概览
简要总结
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products" for Adults Aged 60 Years and Older
详细描述
An open comparative multicenter prospective study with retrospective data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 60 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Volunteers must meet the following inclusion criteria:
- •Type of participants
- •Healthy volunteers or volunteers with a history of stable diseases that do not meet any of the criteria for non-inclusion in the study.
- •Other inclusion criteria
- •Written informed consent of volunteers to participate in a clinical trial
- •Volunteers who are able to fulfill the Protocol requirements (i.e., fill out a self-observation Diary, come to control visits).
排除标准
- •SARS-CoV-2 infection • A case of established COVID-19 disease confirmed by PCR and/or ELISA in the last 6 months.
- •Diseases or medical conditions
- •Serious post-vaccination reaction (temperature above 40 C, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination.
- •Burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.).
- •Guillain-Barre syndrome (acute polyradiculitis) in the anamnesis.
- •The axillary temperature at the time of vaccination is more than 37.0 ° C.
- •Acute infectious diseases (recovery earlier than 4 weeks before vaccination) according to anamnesis.
- •Donation of blood or plasma (in the amount of 450 ml or more) less than 2 months before inclusion in the study.
- •Severe and/or uncontrolled diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, gastrointestinal tract, liver, kidneys, hematopoietic, immune systems.
- •Is registered at the dispensary for tuberculosis, leukemia, oncological diseases, autoimmune diseases.
- •Any confirmed or suspected immunosuppressive or immunodeficiency condition in the anamnesis.
- •Splenectomy in the anamnesis.
- •Neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l) according to anamnesis.
- •Anorexia according to anamnesis.
- •Prior or concomitant therapy
- •Vaccination with any vaccine carried out within 30 days before vaccination / the first dose of the studied vaccine or planned administration within 30 days after vaccination / the last dose of the studied vaccine.
- •Prior vaccination with an experimental or registered vaccine that may affect the interpretation of the study data (any coronavirus or SARS vaccines).
- •Long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs (immunoregulatory peptides, cytokines, interferons, immune system effector proteins (immunoglobulins), interferon inducers (cycloferon) during the six months preceding the study, according to anamnesis.
- •Treatment with systemic glucocorticosteroids (≥ 20 mg of prednisone, or an analog, for more than 15 days during the last month).
- •Volunteers who received immunoglobulin preparations or blood transfusion during the last 3 months prior to the start of the study according to anamnesis.
- •Other non-inclusion criteria
- •Participation in any other clinical trial within the last 3 months.
- •Exclusion criteria:
- •Withdrawal of Informed consent by a volunteer;
- •The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol;
- •Any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study;
- •Taking unauthorized medications (see section 6.2);
- •The volunteer refuses to cooperate or is undisciplined (for example, failure to attend a scheduled visit without warning the researcher and/or loss of communication with the volunteer), or dropped out of observation;
- •For administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as in case of gross violations of the Protocol that may affect the results of the study.
结局指标
主要结局
Frequency of development, type and association with vaccination of adverse events during the study.
时间窗: 6 month
Frequency of development, type and association with vaccination of adverse events during the study.
Titer of specific antibodies
时间窗: 21 days
The proportion of volunteers from the total number of vaccinated with the level of seroconversion (titer of specific antibodies = 4 times the baseline level) on 21 days after the course of vaccination in the reaction of viral neutralization and / or ELISA.
GMT on day 21 after the course of vaccination
时间窗: 21 days
The proportion of volunteers with an increase in the level of immune response in the form of geometric mean titers of specific antibodies (GMT) on day 21 after the course of vaccination in the reaction of viral neutralization and / or ELISA.
The frequency of occurrence of clinically significant deviations from the norm of the main indicators of vital functions and laboratory parameters.
时间窗: 6 month
The frequency of occurrence of clinically significant deviations from the norm of the main indicators of vital functions and laboratory parameters.
次要结局
- ARVI, COVID-19(6 month)
研究者
研究点 (13)
Loading locations...
相似试验
招募中
3 期
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)Coronavirus InfectionsVaccineNCT05407142Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products29,000
已完成
3 期
Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.Rotavirus InfectionsRotavirus VaccinesNCT05037435Limited Liability Company Pharm Aid40
Unknown
不适用
Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell TransplantationHepatitis B ReactivationHematopoietic Stem Cell TransplantationAntiviral DrugHBVNCT04942886Seoul St. Mary's Hospital226
已完成
3 期
Tacrolimus Versus Cyclosporine for Immunosuppression After Lung TransplantationBronchiolitis ObliteransImmunosuppressionNCT01429844Universitätsklinikum Hamburg-Eppendorf274
已完成
4 期
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)HIV InfectionNCT01576731Hospital Clinic of Barcelona240